Vitamin E Phosphate Nucleoside Prodrugs: A Platform for Intracellular Delivery of Monophosphorylated Nucleosides

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Tumor resistance to nucleoside therapeutics limits efficacy.
• Vitamin E (VE) isoforms exhibit anti-cancer activity and chemosensitization.
• Gemcitabine is a widely used chemotherapeutic agent.

Purpose of the Study:

• To design and evaluate novel vitamin E phosphate (VEP) nucleoside prodrugs of gemcitabine.
• To assess the ability of VEP prodrugs to bypass tumor resistance mechanisms.
• To demonstrate the therapeutic utility of VEP-gemcitabine conjugates in preclinical cancer models.

Main Methods:

• Conjugation of four VE isoforms with gemcitabine at the 5' position.
• Evaluation of intracellular gemcitabine-monophosphate (gemcitabine-MP) delivery independent of nucleoside transport.
• Pharmacokinetic assessment of VEP prodrug half-life in mice.
• Assessment of tumor growth inhibition and survival in a non-small cell lung cancer (NSCLC) xenograft mouse model.

Main Results:

• δ-tocopherol-monophosphate gemcitabine (NUC050) demonstrated nucleoside transport-independent delivery of gemcitabine-MP with a half-life of 3.9 h.
• NUC050 significantly inhibited tumor growth and improved median survival in an NSCLC xenograft model compared to saline control.
• NUC050 showed superior tumor growth inhibition compared to historical gemcitabine treatment data.
• δ-tocotrienol-monophosphate gemcitabine (NUC052) also demonstrated significant tumor growth inhibition and improved survival in the NSCLC model.

Conclusions:

• Vitamin E phosphate (VEP) nucleoside prodrugs, specifically NUC050 and NUC052, are effective in delivering gemcitabine and overcoming tumor resistance.
• These novel VEP-gemcitabine prodrugs exhibit significant anti-tumor activity and improve survival in preclinical NSCLC models.
• NUC050 and NUC052 demonstrate safety and efficacy, representing promising therapeutic candidates for cancer treatment.